Equities

Orexo AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Orexo AB

Actions
  • Price (USD)2.60
  • Today's Change0.00 / 0.00%
  • Shares traded2.00
  • 1 Year change+76.27%
  • Beta--
Data delayed at least 15 minutes, as of Dec 17 2025 14:37 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

  • Revenue in USD (TTM)43.36m
  • Net income in USD-22.57m
  • Incorporated1994
  • Employees72.00
  • Location
    Orexo ABP.O. Box 303UPPSALA 751 05SwedenSWE
  • Phone+46 187808800
  • Fax+46 187808888
  • Websitehttps://orexo.se/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
LifeVantage Corp210.05m7.86m62.94m232.008.201.915.840.29970.59980.599816.162.583.242.4596.73905,370.7012.129.1718.9114.0878.7580.733.742.931.03--0.0035.0614.17-0.3794233.84-3.22-12.55--
MindWalk Holdings Corp15.00m-22.77m63.97m102.00--4.86--4.26-0.6327-0.61440.35180.28190.47456.674.50---72.01-32.32-90.53-36.4558.5055.79-151.78-100.974.09-23.680.17--0.008211.77-11.25--10.37--
Pelthos Therapeutics Inc7.41m-23.58m66.82m4.00--1.15--9.02-17.09-17.096.0218.850.1152----1,851,500.00-36.68---47.05--68.73---318.41--1.04-12.320.00-------7.78------
Pliant Therapeutics Inc0.00-175.50m69.44m171.00--0.3467-----2.87-2.870.003.260.00----0.00-48.60-38.70-52.81-41.26-------1,044.87----0.1319---100.00---30.35--31.90--
Scilex Holding Co40.36m-375.84m70.14m30.00------1.74-33.18-33.184.08-28.880.21457.271.85350,956.50-177.73------68.5975.06-828.56-176.540.0429-3.76----21.0721.8956.40---49.14--
NovaBay Pharmaceuticals Inc2.83m-7.95m75.30m14.00------26.61-1.580.53770.5550.27180.7686--5.28202,142.90-215.92-61.58-404.37-83.7954.5659.49-280.92-77.39---91.560.0836---33.588.1948.52---20.59--
Assertio Holdings Inc137.35m-28.92m78.35m58.00--0.740535.500.5704-4.71-4.7120.9316.490.46111.351.472,368,138.00-9.71-15.74-17.07-24.1968.1682.29-21.06-42.011.43--0.2702---17.83-11.4593.50------
Polypid Ltd0.00-34.22m83.56m57.00--4.97-----2.98-2.980.000.92370.00----0.00-147.37-90.05-241.51-109.86-----------22.380.1359-------21.61---38.71--
Verrica Pharmaceuticals Inc30.83m-26.01m88.90m71.00------2.88-3.44-3.443.50-1.800.83521.098.75434,211.30-70.48-71.91-217.79-111.9191.36---84.38-729.001.18-1.701.94--47.66---14.31---47.58--
Biostem Technologies Inc235.17m20.20m92.64m67.006.121.854.530.39390.90190.901911.602.982.822.614.65--24.25--55.07--97.33--8.59--4.09--0.0566--1,708.93--475.86------
Fortress Biotech Inc62.30m-5.34m108.32m101.00--1.94--1.74-0.293-0.2932.161.800.40391.504.35616,861.40-34.90-54.95-51.59-102.1371.5662.39-86.41-227.711.97-10.630.4503---31.769.5018.61--25.88--
Orexo AB - ADR43.36m-22.57m108.97m72.00--1.63--2.51-0.65062.071.251.600.40731.292.02602,258.70-21.20---29.75--89.96---52.04--3.70-3.000.5005---12.46--15.63------
Alpha Cognition Inc7.43m-19.47m115.23m52.00--2.54--15.52-1.37-1.370.50022.090.2894--5.22142,830.80-75.87-119.10-93.86-159.0573.09---262.18--6.03-7.910.00-------6.34------
Whitehawk Therapeutics Inc14.38m-15.62m141.86m22.0022.160.9026--9.860.13580.13580.28023.330.11380.56694.40359,600.00-12.36-52.97-13.76-60.6389.22---108.58-372.6716.76--0.00--6.69--3.15--47.49--
NDT Pharmaceuticals Inc-100.00bn-100.00bn150.40m1.00--0.8397----------1.12-----------164.47---452.47-------6,891.36----0.00---100.00--87.56------
Data as of Dec 17 2025. Currency figures normalised to Orexo AB's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.